BEAM Beam Therapeutics Inc
Company Analysis
Latest News
🔴 Beam Therapeutics is trading 4% down on October 14, 2026, amid broad market and sector weakness
Beam Therapeutics is trading at $23.45, down 4.01%, in live trading as hotter-than-expected September core inflation and rising yields weigh on growth-oriented...
🟢 Beam Therapeutics is trading 4.38% up in pre-market after 40 mg cohort showed controlled fasting
Beam Therapeutics is trading 4.38% higher at $25.50 in pre-market after announcing initial Phase 1/2 BEAM-301 data on October 13, 2026; sources do not directly...
Beam Therapeutics Reports 15-Hour Fasts in GSDIa Trial
Beam Therapeutics announced positive initial data from its Phase 1/2 trial of BEAM-301, an investigational base-editing therapy for glycogen storage disease...
🟢 Beam Therapeutics rises 5.6% — Biotech Sector Rallies on Strong IPO Debuts and M&A Activity
With Biotech (XBI) up 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a significant rally,...
🟢 Beam Therapeutics is trading 5.2% up in pre-market with no clear catalyst identified
Beam Therapeutics is trading at $27.00, up 5.18%, with no confirmed company-specific catalyst identified. - No clear company-specific announcement dated...
🟢 Beam Therapeutics is trading 4.5% up amid broader market strength
Beam Therapeutics is trading 4.49% higher at $25.60 on October 5, 2026, with broader market gains appearing to support the move. - The S&P 500 is up 0.70% and...
Beam Therapeutics Sues Chinese Biotech, Former Scientist Over Trade Secrets
Beam Therapeutics has sued a Chinese biotech startup and one of its former scientists, alleging theft of crucial intellectual property. The complaint, filed in...
🔴 Beam Therapeutics is trading 4.74% down today after Anthropic's Claude identified a CRISPR-like enzyme system
Beam Therapeutics is trading 4.74% down at $23.21 after Anthropic reported that Claude identified a previously unknown CRISPR-like enzyme system, raising...
🔴 Beam Therapeutics is trading 4.4% down today as oil-driven inflation concerns lift Treasury yields
Beam Therapeutics is trading 4.4% lower at $24.79 as broader market and risk-off conditions weigh on U.S. equities. - The Nasdaq Composite is down 1.03%, while...
🟢 Beam Therapeutics rises 4.8% — Biotech Sector Rallies on Major AI Collaboration Deal and Positive Clinical News
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector is trading higher, driven by a...
🟢 Beam Therapeutics is trading 5% up today as markets rebound after Fed decision
Beam Therapeutics is trading 5.06% up at $24.27 as U.S. markets rally following easing policy uncertainty after the Federal Reserve’s September 16 rate...
🔴 Beam Therapeutics falls 4.0% — Biotech Sector Declines on Key Drug Trial Failure and Shifting Investor Sentiment
With Biotech (XBI) down 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, as measured by the XBI ETF, fell...
🔴 Beam Therapeutics is trading 4.2% down today after BEAM-302 safety concerns
Beam Therapeutics is trading at $24.13, with a -4.15% move, as investors continue weighing updated BEAM-302 Phase 1/2 safety findings. • Infusion-related...
🔴 Beam Therapeutics is trading 4% down today after BEAM-302 safety concerns
Beam Therapeutics is trading 4% down at $25.75 after investors focused on safety findings in updated BEAM-302 Phase 1/2 data. - Efficacy appeared durable, but...
🔴 Beam Therapeutics is trading 13% down today
Beam Therapeutics is trading 13% down now at $25.80, after falling from the September 4 close of $29.66; the immediate catalyst remains unclear. - On...
🔴 Beam Therapeutics is trading 6.2% down today in pre-market; cause remains unclear
Beam Therapeutics is trading 6.2% down at $27.83 in pre-market, with available company materials not establishing that the positive update caused the...
Beam Therapeutics Surges 9% on Fresh Gene-Editing Data — But Can a One-Time Cure Justify a $3 Billion Bet?
Shares shifted sharply as Beam Therapeutics jumped +9.1% to $32.36 ahead of a morning investor webcast and late-breaking presentation at the European...
🟢 Beam Therapeutics is trading 9.09% up today in pre-market due to positive BEAM-302 data presented at ERS Congress
Beam Therapeutics is trading at $32.36 (+9.09%) as shares rise following the presentation of positive updated BEAM-302 data at the European Respiratory Society...
Farallon Capital Discloses New $241.51M Stake in Beam Therapeutics
In a recent filing, Farallon Capital Management revealed it had established a significant new position in Beam Therapeutics (BEAM), a biotechnology company...
🔴 Beam Therapeutics falls 4.1% — Biotech Sector Declines Amid Fed Rate Hike Fears
With Biotech (XBI) down 2.3%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, as measured by the XBI ETF, fell...